Paladin Partners’s NervGen Pharma NGEN Stock Holding History

Paladin Partners’s Portfolio NGEN Stock Details NGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$19.1K	Hold	10,000	–	–	0.01%	110
2026 Q2	$20.6K	Hold	10,000	–	–	0.01%	109
2026 Q1	$37.7K	Hold	10,000	–	–	0.03%	78
2025 Q4	$56K	Buy	+10,000	New	+$56K	0.04%	62

Other funds holding NGEN

McKinley Carter Wealth Services Wheeling, West Virginia $1.96B AUM 13.62% 1-Year Est. Return

Patriot Financial Group Insurance Agency Westborough, Massachusetts $1.05B AUM 21.28% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Paladin Partners's NGEN Position: Q3 2026 in Review

Paladin Partners held its NervGen Pharma (NGEN) position steady in Q3 2026 at 10,000 shares worth $19.1K. The position accounts for 0.01% of the portfolio, ranked #110.

Paladin Partners first reported a position in NGEN in Q4 2025 and has held it in 4 quarters since. The position peaked at $56K in Q4 2025. 6 funds tracked by Wall St. Rank hold NGEN as of Q3 2026.

Paladin Partners held 10,000 shares of NervGen Pharma worth $19.1K as of Q3 2026.
Paladin Partners left its NervGen Pharma share count unchanged in Q3 2026.
NervGen Pharma made up 0.01% of Paladin Partners's portfolio in Q3 2026, its #110 holding.
Paladin Partners first reported a position in NervGen Pharma in Q4 2025 and has held it in 4 quarters since.
Paladin Partners's NervGen Pharma position peaked at $56K in Q4 2025.
6 funds tracked by Wall St. Rank held NervGen Pharma as of Q3 2026.

Based on Paladin Partners's 13F filing for Q3 2026, filed 6 Oct 2026.